EyePoint, Inc.EYPTEarnings & Financial Report
Nasdaq · pharmaceutical industry
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
NextMar 19, 2026
EYPT Q3 2025 Key Financial Metrics
营收
$966.0K
毛利润
N/A
营业利润
$-62.0M
净利润
$-59.7M
毛利率
N/A
营业利润率
-6420.8%
净利率
-6183.4%
同比增长
-90.8%
EPS
$-0.85
资金流向
EyePoint, Inc. Q3 2025 Financial Summary
EyePoint, Inc. reported revenue of $966.0K for Q3 2025, with a net profit of $-59.7M (-6183.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $966.0K |
|---|---|
| Net Profit | $-59.7M |
| Gross Margin | N/A |
| Operating Margin | -6420.8% |
| Report Period | Q3 2025 |
EyePoint, Inc. Annual Revenue by Year
EyePoint, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $43.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $43.3M |
| 2023 | $46.0M |
| 2022 | $41.4M |
利润表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $14.0M | $11.7M | $9.5M | $10.5M | $11.6M | $24.5M | $5.3M | $966000 |
| 同比增长 | 33.2% | 52.1% | 4.1% | -30.8% | -17.4% | 109.3% | -43.7% | -90.8% |
资产负债表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $355.2M | $329.2M | $324.2M | $300.9M | $418.5M | $362.6M | $301.1M | $251.7M |
| 总负债 | $88.9M | $79.3M | $95.9M | $82.2M | $82.0M | $64.2M | $55.1M | $51.5M |
| 股东权益 | $266.3M | $249.9M | $228.3M | $218.7M | $336.5M | $298.4M | $246.0M | $200.2M |
现金流量表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $-23.1M | $-31.2M | $-20.2M | $-39.0M | $-35.8M | $-53.1M | $-62.6M | $-59.4M |
